(Reuters) -Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug, Mounjaro, in countries like China, India, ...

Consumers who use telehealth or medical spas to get less expensive, compounded weight loss drugs will need to get their ...

After Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk has cut the price of weight ...

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

Eli Lilly plans to globally launch its diabetes and weight-loss drug, Mounjaro, in countries including China, India, Brazil, ...

Eli Lilly plans to release its diabetes and weight-loss drug, Mounjaro, in major global markets like China, India, Brazil, ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

A U.S. federal judge has refused to allow compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss and ...

Compounded GLP-1s have given rise to a cottage industry offering cheaper weight loss medications to many Americans — but now ...

How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about Ozempic's and Mounjarno's patent cliffs. The scenarios in which Novo ...

Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...